Cardiac allograft vasculopathy remains a major limiting factor in long-term survival after heart transplantation, though advances in imaging, diagnostics, and pharmacology are improving management.
This review highlights the evolving understanding of cardiac allograft vasculopathy pathogenesis, diagnostic modalities, and pharmacological advances in heart transplant recipients.
Cardiac allograft vasculopathy remains a major limiting factor in the long-term survival of the heart transplant recipient. Our understanding of its pathogenesis is continuously evolving as advances in imaging modalities have allowed a direct window into the natural history of the disease. Innovation in diagnostic modalities has spurred the proliferation of prognostic tools and biomarkers. And in parallel, pharmacological advances have emerged that have helped ameliorate the disease's progressive course.
Nikolova et al. (Wed,) conducted a review in Cardiac allograft vasculopathy. Cardiac allograft vasculopathy remains a major limiting factor in long-term survival after heart transplantation, though advances in imaging, diagnostics, and pharmacology are improving management.